Prostate spesific membrane antigen single photon emission computed tomography in staging of prostate cancer: a randomised trial
Phase 1
- Conditions
- Prostate cancerTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Registration Number
- EUCTR2021-000486-33-FI
- Lead Sponsor
- Turku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Male
- Target Recruitment
- 320
Inclusion Criteria
Histopathologically confirmed high risk (Gleason =4+4, PSA =20 and/ or cT=3a) acinar or ductal adenocarcinoma of prostate
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 160
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 160
Exclusion Criteria
Subjects who are previously treated due to prostate cancer
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method